
Experts FINALLY pinpoint cause of autism - landmark discovery paves the way for drug treatments
While it has long been understood that autism often runs in families, exactly how inherited changes in DNA lead to the condition has remained unclear.
Now, researchers at Kobe University in Japan have found that many of the mutations associated with autism appear to disrupt the brain's natural 'maintenance' system—the internal process that clears out waste and damaged material, allowing brain cells to function as they should.
When this clean-up system fails, as the study suggests it does in many cases of autism, waste begins to build up inside nerve cells, damaging their ability to send and receive signals.
This breakdown may help explain some of the core features of autism, including difficulties with learning, language and social interaction.
The research, published in Cell Genomics, focused on identifying what different high-risk genetic variants actually do inside the brain.
Scientists have known for years that certain genetic mutations are more common in people with autism—but until now, there was no standardised way to study the effects of those mutations in the lab.
To solve this, the Kobe team created a library of 63 specially engineered cell lines—groups of cells grown in the lab that are genetically identical, allowing researchers to conduct consistent experiments.
Each line carried one of the genetic mutations most strongly associated with autism spectrum conditions (ASC).
These cells were created using mouse embryonic stem cells—taken from early-stage mouse embryos—which have the unique ability to develop into any kind of tissue in the body, including brain cells.
No human embryos were used.
To introduce the mutations, the scientists used CRISPR, a gene-editing technology that allows precise changes to DNA.
It enabled the team to effectively model autism in the lab—creating what some researchers describe as 'autism in a dish.'
From these modified cells, the team was able to grow various types of brain tissue—and even generate adult mice with the same mutations—giving them a powerful way to study how genetic changes affect both brain structure and behaviour over time.
What they found was striking. Across many of the mutations, a common problem emerged: the brain's waste-disposal system wasn't working properly.
Brain cells—particularly neurons, which carry electrical signals and control thought, emotion, and behaviour—were struggling to get rid of faulty internal components.
As the study puts it, 'a lack of quality control of these proteins may be a causal factor of neuronal defects.'
The authors note this is 'particularly interesting since the local production of proteins is a unique feature in neurons.'
In simple terms, neurons are constantly producing new components to help them send messages.
But if they can't clear out old or broken parts, the system becomes clogged and starts to malfunction—potentially disrupting the brain networks that support communication, learning and social development.
The implications may go beyond autism.
Many of the same genetic mutations are also found in people with other mental health conditions, such as schizophrenia and bipolar disorder.
As the authors note: 'Interestingly, the genetic variants we studied are also implicated in other neuropsychiatric disorders such as schizophrenia and bipolar disorder.
'So, this library may be useful for studying other conditions as well.'
The researchers hope that by better understanding what these mutations do, scientists will be able to identify new drug targets—and eventually, develop treatments tailored to a person's unique genetic profile.
While any clinical application is still likely years away, the discovery marks a turning point in autism research—moving beyond simply spotting risk genes to uncovering the biological chain of events that may cause the condition in the first place.
It follows soaring rates of autism—with a 787 per cent rise in the number of diagnoses in the UK between 1998 and 2019 reported in a 2021 study.
Last month NHS data showed that more than 200,000 people—triple that in 2021—are waiting for an autism assessment in England.
Famous figures with ASC include environmental activist Greta Thunberg, 22, and billionaire entrepreneur Elon Musk, 53, founder of Tesla and owner of X (formerly Twitter).
As the condition affects people in many different ways, some autistic individuals do not view it as an illness requiring a 'cure'.
Instead, they see it as a difference—one that should be understood and accommodated, rather than treated or fixed.
The Kobe University research is not the first to examine genetic links to the condition to provide an answers.
Earlier this year, experts found some cases of autism may be caused by the genetic condition myotonic dystrophy type 1 (DM1).
Those with the little-known genetic condition were found to be 14 times more likely to develop autism.
Other studies have suggested environmental factors could be a potential cause of autism.
Last year, research found a common plastic additive found in everything from pacifiers to metal foods had been linked to an increased risk of autism in boys.
It found that higher levels of chemical bisphenol A (BPA) in a pregnant mother's urine more than tripled the chances a young boy developing autism symptoms by the age of two.
Those same boys were six times more likely to be diagnosed with autism by age 11 — compared to those whose mothers had lower BPA levels during pregnancy.
The chemical BPA is intended to harden plastics and prevent metals from rusting, among other uses.
It has also been dubbed a 'gender-bending' chemical due to its apparent role spurring hormonal and sexual disruptions in humans, fish and other species.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
2 hours ago
- The Independent
NHS plan to achieve precision-matched blood transfusions
The NHS has launched a pioneering initiative to identify and secure blood donations from individuals with rare blood types, aiming to provide "precision-matched" transfusions. As part of this UK-first drive, scientists have DNA-tested the blood of 77,000 donors to date, with the goal of identifying hundreds more rare donors. Blood collected from these rare donors will be frozen to create a vital reserve, which will also be available to the donors themselves if they require a transfusion. This large-scale DNA testing helps to mitigate the risk of severe transfusion reactions, particularly for patients who regularly receive blood, such as those with sickle cell disorder and thalassaemia. NHS Blood and Transplant highlights the critical importance of precise blood matching due to the 362 known blood types, calling this project a significant step towards wider precision-matched blood use.


The Guardian
5 hours ago
- The Guardian
‘Slip, slop, slap for brain health': Australia needs a major prevention campaign for dementia, doctor says
A 'slip, slap, slop'-style preventative campaign is needed for dementia, as new research shows cases of the disease could be delayed with no added cost, a leading doctor has told the National Press Club on Wednesday. In the speech titled 'Hope Beckons', Prof Henry Brodaty, a co-director of the Centre for Healthy Brain Ageing (CHeBA) at the University of New South Wales, said there was much more Australia could be doing to help prevent dementia in its ageing population by addressing risk factors that can be managed, such as poor diet. Australia has a 'very proud record of prevention' when it comes to health, such as the 'slip slap slop' and 'life be in it' campaigns, as well as smoking reduction and heart health awareness, Brodaty said. 'But we don't have an awareness in our community we can do the same thing for dementia, where half the risk factors for dementia is caused by environmentally modifiable factors that we can all do something about. 'We all have the power to do more exercise, to keep our brains active, keep socially connected. We can monitor and treat high blood pressure, high cholesterol. We can compensate for hearing loss. We can try to avoid obesity. We can reduce the risk of diabetes and head injury. We can live in environments free of air pollution. We can not smoke and avoid excess alcohol.' Brodaty told the press club 'We need the slip, slop, slap of brain health now.' Sign up: AU Breaking News email The National Dementia Action Plan 2023–2034 was released, but $166m in funding is too little for what Australia needs, he said. 'Where are the navigators to guide patients and families after a diagnosis? Think about breast cancer … We can do this too in dementia, and it can be cost neutral,' Brodaty said. A study on which Brodaty was senior author, published on Wednesday in the Journal of Prevention of Alzheimer's Disease, found that CHeBA's internet-based dementia prevention program tailored to an individual's risk profile shows cost-effectiveness for improving cognition and reducing dementia risk. Between 2018 and 2021, the trial followed 6,104 Australians aged 55 to 77 without dementia but who carried at least two modifiable dementia risk factors such as being overweight or suffering from anxiety. CHeBA's 'Maintain Your Brain' online had coaching modules for four of these factors: physical activity, nutrition, cognitive training, and depression or anxiety. Half of the participants were assigned to the online program, where they were allocated between two to four of the modules depending on their dementia risk profile, while the other half of participants in the trial (the control group) were given access to curated but freely available information sheets regarding dementia risk reduction. After three years, the researchers analysed the differences in costs for both the direct healthcare that participants received and the program costs, and the effectiveness (cognitive outcomes and dementia risk) between the two groups. They found the participants who received the online coaching showed significant improvements in cognitive performance and greater reductions in dementia risk compared with those who received general health information alone. The difference was highly significant, which would have a 'major effect' at a population level, delaying the onset of dementia, Brodaty said. 'Every year that we can delay the onset of dementia reduces the prevalence of dementia by 10% because it pushes the disease to later in life.' Sign up to Breaking News Australia Get the most important news as it breaks after newsletter promotion They also found there was no significant difference in cost per person over the trial period because those who participated in the program used fewer healthcare resources which offsets the cost of delivering it. The researchers noted that the online program would become cheaper per person in future because some research and development costs had already been borne. The researchers also acknowledged limitations within the study: the participants were primarily Caucasian, better educated than average and had a higher socioeconomic status than the general population. They also noted risk-reduction practices may reap greater benefits in higher-risk populations. As the study, they said, considered short-term measures of effectiveness only, 'the true long-term cost savings will only be known if the sample is followed long enough to identify whether cases of incident dementia are prevented'. Prof Scott Ayton, a director in dementia research at the Florey Institute of Neuroscience and Mental Health, who was not involved in the research, said 'evidence accumulated over the past decade indicates that lifestyle and risk factor-targeted prevention strategies can meaningfully lessen dementia risk'. 'The large Maintain Your Brain trial stands as a leading exemplar, showing that straightforward, cost-effective, risk-factor targeted interventions can delay onset or reduce overall risk without adding pressure to the health budget,' Ayton said.


The Independent
6 hours ago
- The Independent
NHS on the hunt for ‘precision-matched' blood donors
The NHS is searching for blood donors with rare blood types so it can ensure patients in need can receive 'precision-matched' blood. Scientists have tested tens of thousands of blood donors to see if they have rare blood types in a UK-first. The blood from donors with rare blood types will be collected and frozen so it can be used to help other people with the same type of blood. It will also be available should the donor be in a situation where they themselves need a blood transfusion. The new drive to find precision-matched blood donors comes to help people who are at risk of blood transfusion side effects. NHS Blood and Transplant (NHSBT) said that blood matching is 'vital' due to the complexity of blood groups – there are 362 known blood types. So far its scientists have DNA-tested the blood types of 77,000 donors as part of a research project. This is the first time that blood types have been DNA tested in the UK at-scale, NHSBT said. Dozens of rare blood donors have been identified during the process and it is hoped the number will rise to hundreds. This means that blood from these donors can be used as 'personalised, precision-matched transfusion' for those in need. This can help avoid severe transfusion reactions – where the body sees the transfused blood as 'foreign' and rejects it. People who are particularly at risk of these reactions are those who regularly receive blood donations including those with sickle cell disorder and thalassaemia. Experts hailed the project as the 'first major step' towards rolling out precision-matched blood more widely. Dr Gail Miflin, chief medical officer at NHSBT, said: 'Taking these 77,000 donors and testing their blood to such a precise level has been an incredible undertaking and will work to significantly change the way we issue blood – especially to those patients at higher risk of transfusion related reactions. 'We will be able to match to an increasing number of blood groups, ensuring that patients have blood that is most similar to their own and reducing the risk of any reactions. It is an example of just how we are driving innovation which can radically improve patient outcomes.' NHSBT's genomics programme director, Kate Downes, added: 'This inventory of blood will enhance our capacity to find units with rare blood groups for difficult to match patients as well as provide better matched units for patients who have an increased risk of transfusion reactions, aiding us in our mission to save and improve even more lives. 'This genotyping is a first major step towards rolling out precision matched blood more widely, which would be a landmark change in how blood is matched.'